Join Richmond Pharamcology at the 2nd DIA Cardiac Safety Workshop in Japan for our latest TQT Analysis in Japanese and Caucasian Volunteers

Posted:
16
August 2011

Richmond Pharmacology Ltd is proud to announce its participation in the �2nd DIA Cardiac Safety Workshop in Japan,� being held September 5-6, 2011 at Tower Hall Funabori in Tokyo, Japan. The meeting will address the key scientific, clinical and regulatory issues of implementation of ICH-E14 in Japan and bring together experts from multiple disciplines; intended to facilitate an open and productive dialogue between regulatory, industry and academic delegates.As a feature, the first ever formal Japanese Caucasian bridging TQT analysis will be presented by Dr Jorg Taubel, CEO and Principal Investigator of Richmond Pharmacology Ltd. The analysis was carried out jointly between the Department of Pharmacology of Toho University, the Cardiovascular Sciences Research Centre at St Georges University of London and Richmond Pharmacology Ltd. This groundbreaking presentation being held on Day 1, Session 3 from 17h00 to 17h30 promises to be an informative and insightful discussion relating to the recent implementation of ICH-E14.Having successfully completed in excess of 50 studies in Japanese subjects since 2002, many of which have already been used in regulatory submissions in Japan, Richmond Pharmacology Ltd is well positioned to conduct TQT Studies in Japanese subjects outside of Japan and for the conduct of TQT Bridging Studies in a mixed Japanese and Caucasian study populations. To learn more about our specialist expertise in Japanese Studies come meet our team at booth numbers 8-9, where Richmond Pharmacology Ltd will be happy to discuss our capabilities in more detail.If you are interested in attending the 2nd DIA Cardiac Safety Workshop in Japan, click here to register or contact a member of our business development team to arrange a meeting in person. We look forward to seeing you in Tokyo!

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Read more

A new era for UK-Japanese scientific relations

March 23, 2021
Dr Taubel uses his experience of conducting more than 60 Japanese bridging studies to explain why the deal is of strategic importance to the UK and highlights the scientific requirements for conducting successful Japanese trials abroad
Read more

Richmond Pharmacology’s local MP Neil Coyle calls on the Government to evaluate the potential of using Clinical Research Organisations.

February 3, 2021
Richmond Pharmacology has offered its services to the Government and the NHS as an additional vaccine site in London
Read more